Civatech Oncology
Durham, US · North Carolina corporation
CivaTech Oncology develops polymer-encapsulated low dose rate brachytherapy devices—including CivaSheet, CivaString, and CivaDerm—used by radiation oncologists to deliver targeted radiation therapy for solid tumors such as prostate, pancreatic, and skin cancers. The company designs and commercializes FDA-cleared, bioabsorbable radiation therapy products for cancer treatment.
Founders & leadership
ST
Suzanne Troxler BabcockFounder
ST
Suzanne T. BabcockNamed on SEC filing
Board
CM
Carlton MidyetteBoard director
RJ
Robert J. Greczyn, Jr.Board director
DC
Delwin CoufalBoard director
TL
Tempe LampeBoard director
Reported raises · per SEC filings
Form D private placements$13.2M disclosed across 7 rounds · 2012–2021
▶$7.9MraisedNov 2021 · 47 investors · Other Health CareRule 506(b)
▶$7.9MraisedNov 2021 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William PullyDirector
- Herb KuhnDirector
- Carlton MidyetteDirector
- James A. BeckDirector
- Tempe LampeDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Offering amount
- $15.2M
- Amount sold
- $7.9M
- Sales commissions
- $159K
- Placement agents
- EuroConsult, Inc.
- First sale
- Nov 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$15KraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$15KraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. Greczyn, Jr.Director
- Tempe LampeDirector
- William PullyDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- James A. BeckDirector
- Carlton MidyetteDirector
- Offering amount
- $2M
- Amount sold
- $15K
- First sale
- Dec 2017
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$916.1KraisedAug 2017 · 9 investors · Other Health CareRule 506(b)
▶$916.1KraisedAug 2017 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tempe LampeDirector
- Carlton MidyetteDirector
- James A. BeckDirector
- Robert J. Greczyn, Jr.Director
- William PullyDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $916.1K
- First sale
- Jul 2017
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$2.7MraisedDec 2016 · 28 investors · Other Health CareRule 506(b)
▶$2.7MraisedDec 2016 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tempe LampeExecutive Officer
- Robert J. GreczynDirector
- Carlton MidyetteDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Delwin CoufalDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- First sale
- Sep 2015
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$10KraisedAug 2016 · 1 investors · Other Health CareRule 506(b)
▶$10KraisedAug 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne Troxler BabcockExecutive Officer, Director
- Carlton MidyetteDirector
- Robert J. Greczyn, Jr.Director
- Delwin CoufalDirector
- Tempe LampeDirector
- Offering amount
- $2M
- Amount sold
- $10K
- First sale
- Jul 2016
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$1.5MraisedJul 2014 · 16 investors · Other Health CareRule 506(b)
▶$1.5MraisedJul 2014 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne Troxler BabcockExecutive Officer, Director
- Tempe LampeExecutive Officer
- Robert J. GreczynDirector
- Delwin CoufalDirector
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$75KraisedMar 2012 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedMar 2012 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne T. BabcockExecutive Officer, Director
- Robert J. Greczyn, Jr.Director
- Tempe LampeDirector
- Delwin CoufalDirector
- Offering amount
- $600K
- Amount sold
- $75K
- First sale
- Mar 2012
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Kiyatec4 shared keywordsKIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
Rarecyte4 shared keywords
Itnonline4 shared keywordsITN (Imaging Technology News) is an online trade publication covering radiology and medical imaging, reporting on news, products, and clinical developments across modalities like CT, ultrasound, and breast imaging. It serves radiology professionals, imaging departments, and healthcare technology providers.
Celcuity4 shared keywordsCelcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
BioCytics4 shared keywordsBioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
Dialectic Therapeutics3 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Kite Pharma3 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Civatech Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $296.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $999K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Civatech Oncology do?
- CivaTech Oncology develops polymer-encapsulated low dose rate brachytherapy devices—including CivaSheet, CivaString, and CivaDerm—used by radiation oncologists to deliver targeted radiation therapy for solid tumors such as prostate, pancreatic, and skin cancers. The company designs and commercializes FDA-cleared, bioabsorbable radiation therapy products for cancer treatment.
- Who founded Civatech Oncology?
- Civatech Oncology was founded by Suzanne Troxler Babcock.
- How much funding has Civatech Oncology raised?
- Civatech Oncology has disclosed $13.2M raised across 7 rounds.
- Where is Civatech Oncology headquartered?
- Civatech Oncology is headquartered in Durham, US.